A STUDY ON THE SHORT TERM EFFECTS OF GRID LASER PHOTOCOAGULATION AND COMBINATION TREATMENT (GRID LASER WITH INTRAVITREAL BEVACIZUMAB) IN THE MANAGEMENT OF DIABETIC MACULAR OEDEMA

被引:0
作者
Agarwal, Adil [1 ]
Thomas, Mary [2 ]
Shankar, Allen R. [2 ]
Sruthi, Shantha M. [2 ]
机构
[1] Agarwals Eye Hosp, Dept Ophthalmol, Madras, Tamil Nadu, India
[2] Sri Ramachandra Med Coll & Res Inst, Dept Ophthalmol, Madras 600116, Tamil Nadu, India
来源
JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS | 2016年 / 5卷 / 36期
关键词
Laser Photocoagulation; Intravitreal Avastin Injection; Combined Therapy; Diabetic Macular Oedema;
D O I
10.14260/jemds/2016/501
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AIM To study the short term effect of grid laser photocoagulation in the treatment of diabetic macular oedema. As a comparison, the short term efficacy of combination treatment of grid laser photocoagulation along with intravitreal injection of bevacizumab was studied in the treatment of Diabetic Macular Oedema (DME). MATERIALS AND METHODS 74 eyes of 43 patients between the ages of 50-60 years with diabetic maculopathy were selected. These patients were then assigned to either groups of standalone photocoagulation therapy (Group I) or combined therapy of photocoagulation with intravitreal Avastin (Group 2). Best Corrected Visual Acuity and Optical Coherence Tomography findings were done in all the patients during a follow-up done every four weeks up to twelve weeks. RESULTS In Group I, at the end of 12 weeks, overall 34% patients showed an improvement or stability in visual acuity. 66% of the patients had a decrease in visual acuity. The number of eyes with decline in visual acuity decreased during 4 to 12 weeks. 59.22% of the eyes showed improvement or stability in the visual acuity in Group 2. The mean central macular thickness remained stable or increased in 70.2% of the eyes, whereas the CMT decreased only in 29.8% eyes. But in Group 2, at the end of 12 weeks, 59.3% had a decrease in CMT. Total Macular Volume (TMV) in Group I, decreased in 57.4% of the eyes. On the other hand, in Group 2 at 12 weeks, 59.3% showed a decrease in TMV, which is slightly better than in Group 1. CONCLUSION The patients with DME who underwent combined photocoagulation with intravitreal injection of Avastin showed significant improvement in visual acuity, central macular thickness and macular volume as compared to the patients who underwent standalone laser photocoagulation, though neither of the groups showed completely satisfactory improvement. Study with large number of patients and long term follow-up would be considered ideal.
引用
收藏
页码:2147 / 2153
页数:7
相关论文
共 25 条
[1]   Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial [J].
Ahmadieh, Hamid ;
Ramezani, Alireza ;
Shoeibi, Nasser ;
Bijanzadeh, Bijan ;
Tabatabaei, Ali ;
Azarmina, Mohsen ;
Soheilian, Masoud ;
Keshavarzi, Gholamreza ;
Mohebbi, Mohammad-Reza .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2008, 246 (04) :483-489
[2]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[3]   Laser photocoagulation of diabetic macular edema [J].
Akduman, L ;
Olk, RJ .
OPHTHALMIC SURGERY AND LASERS, 1997, 28 (05) :387-408
[4]  
BLANKENSHIP GW, 1979, OPHTHALMOLOGY, V86, P69
[5]   Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen [J].
Chen, Y ;
Wiesmann, C ;
Fuh, G ;
Li, B ;
Christinger, HW ;
McKay, P ;
de Vos, AM ;
Lowman, HB .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (04) :865-881
[6]  
Coscas G, 2010, DEV OPHTHALMOL, V47, P1, DOI 10.1159/000320070
[7]   A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema [J].
Cunningham, ET Jr ;
Adamis, AP ;
Altaweel, M ;
Aiello, LP ;
Bressler, NM ;
D'Amico, DJ ;
Goldbaum, M ;
Guyer, DR ;
Katz, B ;
Patel, M ;
Schwartz, SD .
OPHTHALMOLOGY, 2005, 112 (10) :1747-1757
[8]  
Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
[9]   Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema [J].
Fang, Xiaoyun ;
Sakaguchi, Hirokazu ;
Gomi, Fumi ;
Oshima, Yusuke ;
Sawa, Miki ;
Tsujikawa, Motokazu ;
Ikuno, Yasushi ;
Kamei, Motohiro ;
Kusaka, Shunji ;
Tano, Yasuo .
ACTA OPHTHALMOLOGICA, 2008, 86 (07) :800-805
[10]   Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema The Pan-American Collaborative Retina Study Group at 24 Months [J].
Fernando Arevalo, J. ;
Sanchez, Juan G. ;
Wu, Lihteh ;
Maia, Mauricio ;
Alezzandrini, Arturo A. ;
Brito, Miguel ;
Bonafonte, Sergio ;
Lujan, Silvio ;
Diaz-Llopis, Manuel ;
Restrepo, Natalia ;
Rodriguez, Francisco J. ;
Udaondo-Mirete, Patricia .
OPHTHALMOLOGY, 2009, 116 (08) :1488-1497